Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study
Martin, Thomas G. (University of California San Francisco, USA)
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Usmani, Saad Z. (Levine Cancer Institute/Atrium Health, Charlotte, NC)
Garfall, Alfred (University of Pennsylvania, Philadelphia, PA)
Mateos, M. V (Hospital Universitario de Salamanca)
San-Miguel, Jesús F. (Clínica Universidad de Navarra)
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Nooka, Ajay K. (Emory University, Atlanta, GA)
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona)
Chari, Ajay (Mount Sinai School of Medicine, New York, USA)
Karlin, Lionel (Centre Hospitalier Lyon Sud, Pierre-Bénite, France)
Krishnan, Amrita (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica))
Bahlis, Nizar (University of Calgary, Canada)
Popat, Rakesh (University College London)
Besemer, Britta (University of Tuebingen, Tuebingen, Germany)
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid))
Delforge, Michel (Universitaire Ziekenhuizen Leuven, Belgium)
Trancucci, Danielle (Janssen Research & Development, Raritan, NJ)
Pei, Lixia (Janssen Research & Development, Raritan, NJ)
Kobos, Rachel (Janssen Research & Development, Raritan, NJ)
Fastenau, John (Janssen Research & Development, Raritan, NJ)
Gries, Katharine S. (Janssen Research & Development, Raritan, NJ)
van de Donk, Niels W.C.J. (Amsterdam University Medical Center, Vrije Universiteit Amsterdam, The Netherlands)

Date:	2023
Abstract:	Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. Therefore, consideration of the impact of treatment on HRQoL in addition to clinical outcomes is vital. Patients and Methods: In the phase I/II MajesTEC-1 (NCT03145181, NCT04557098) study, patients with RRMM who received teclistamab, an off-the-shelf, T-cell redirecting BCMA × CD3 bispecific antibody, had deep and durable responses with manageable safety. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30-item and the EuroQol 5 Dimension 5 Level descriptive questionnaire. Changes over time from baseline were measured with a repeated measures mixed-effects model. Proportions of patients with clinically meaningful improvement after starting treatment and time to clinically meaningful worsening were assessed. Results: Compliance was maintained throughout the study. Compared with baseline, positive changes were observed for pain, global health status, and emotional functioning with treatment; other assessments were largely unchanged from baseline. Post hoc analysis showed patients with deeper clinical response generally reported improved HRQoL outcomes. Following an initial decline in HRQoL in some scales, the proportion of patients reporting clinically meaningful improvements increased, while the proportion reporting clinically meaningful worsening decreased over time. Clinically meaningful improvements in pain were reported in ≥40% of patients at most assessment time points. Conclusions: These results complement previously reported clinical benefits and support teclistamab as a promising therapeutic option for patients with RRMM.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Clinical Lymphoma, Myeloma & Leukemia, 2023 , ISSN 2152-2669

DOI: 10.1016/j.clml.2023.11.001

9 p, 603.3 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles